北京希而欧生物医药开发有限公司

Beijing CRO Biological Pharmaceutical Development Co., Ltd. is a leading Chinese contract research organization (CRO) that provides comprehensive clinical development services to global and domestic pharmaceutical and medical device companies. Established in 2000, it was one of the earliest professional CROs in China, specializing in regulatory consulting, clinical trial management, data management, and biostatistics. The company played a pivotal role in bridging the gap between Chinese clinical research and international standards, such as ICH-GCP. Following its integration into Fountain Medical Development (FMD), the company became part of a larger global network through a merger with dMed. In 2022, the combined organization rebranded as ClinChoice, under which Beijing CRO continues to operate as a key regional hub.